Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder.

Liput DJ, Hammell DC, Stinchcomb AL, Nixon K.

Pharmacol Biochem Behav. 2013 Oct;111:120-7. doi: 10.1016/j.pbb.2013.08.013. Epub 2013 Sep 5. Erratum in: Pharmacol Biochem Behav. 2014 Nov;126:187-8.

2.

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN.

Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30.

3.

Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.

Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E.

J Control Release. 2003 Dec 12;93(3):377-87.

PMID:
14644587
4.

Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.

Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, Hallak JE, Zuardi AW, Quevedo J, Crippa JA.

J Psychopharmacol. 2011 Feb;25(2):274-80. doi: 10.1177/0269881109106925. Epub 2009 Nov 25.

PMID:
19939866
5.

Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity.

Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL.

J Pharmacol Exp Ther. 2005 Aug;314(2):780-8. Epub 2005 May 5.

6.

Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers.

Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL.

Drug Dev Ind Pharm. 2010 Sep;36(9):1088-97. doi: 10.3109/03639041003657295.

PMID:
20545522
7.

Binge Alcohol Exposure Transiently Changes the Endocannabinoid System: A Potential Target to Prevent Alcohol-Induced Neurodegeneration.

Liput DJ, Pauly JR, Stinchcomb AL, Nixon K.

Brain Sci. 2017 Nov 29;7(12). pii: E158. doi: 10.3390/brainsci7120158.

8.

Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.

Campos AC, Ferreira FR, Guimarães FS.

J Psychiatr Res. 2012 Nov;46(11):1501-10. doi: 10.1016/j.jpsychires.2012.08.012. Epub 2012 Sep 11.

PMID:
22979992
9.

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.

Kozela E, Juknat A, Vogel Z.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1669. doi: 10.3390/ijms18081669. Review.

10.

Cannabidiol, neuroprotection and neuropsychiatric disorders.

Campos AC, Fogaça MV, Sonego AB, Guimarães FS.

Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Review.

PMID:
26845349
11.

Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Walsh SK, Hepburn CY, Kane KA, Wainwright CL.

Br J Pharmacol. 2010 Jul;160(5):1234-42. doi: 10.1111/j.1476-5381.2010.00755.x.

12.

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.

Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA.

Can J Vet Res. 2018 Jul;82(3):178-183.

PMID:
30026641
13.

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6.

14.

Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function.

Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J.

Neuropharmacology. 2012 Oct;63(5):776-83. doi: 10.1016/j.neuropharm.2012.05.034. Epub 2012 May 30.

PMID:
22659086
15.

Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.

Gomes FV, Del Bel EA, Guimarães FS.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:43-7. doi: 10.1016/j.pnpbp.2013.06.005. Epub 2013 Jun 19.

16.

Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats.

Chagas MH, Crippa JA, Zuardi AW, Hallak JE, Machado-de-Sousa JP, Hirotsu C, Maia L, Tufik S, Andersen ML.

J Psychopharmacol. 2013 Mar;27(3):312-6. doi: 10.1177/0269881112474524. Epub 2013 Jan 23.

PMID:
23343597
17.

Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury.

Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, Beeri R, Pugatsch T, Tarsish E, Lotan C.

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3602-7. Epub 2007 Sep 21.

18.

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats.

Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS.

Br J Pharmacol. 2009 Jan;156(1):181-8. doi: 10.1111/j.1476-5381.2008.00046.x.

19.
20.

Cannabidiol reduces ethanol consumption, motivation and relapse in mice.

Viudez-Martínez A, García-Gutiérrez MS, Navarrón CM, Morales-Calero MI, Navarrete F, Torres-Suárez AI, Manzanares J.

Addict Biol. 2018 Jan;23(1):154-164. doi: 10.1111/adb.12495. Epub 2017 Feb 13.

PMID:
28194850

Supplemental Content

Support Center